Skip to Main content Skip to Navigation
Journal articles

Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.

Abstract : Gamma delta (γδ) Τ cells are non-conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti-tumour activity against many cancers and suggest that γδ Τ cell-mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.
Document type :
Journal articles
Complete list of metadata

Cited literature [93 references]  Display  Hide  Download
Contributor : Monique Frei Connect in order to contact the contributor
Submitted on : Wednesday, March 20, 2013 - 11:39:41 AM
Last modification on : Tuesday, March 15, 2022 - 9:38:03 AM
Long-term archiving on: : Sunday, April 2, 2017 - 3:38:15 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Mounia S. Braza, Bernard Klein. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.. British Journal of Haematology, Wiley, 2013, 160 (2), pp.123-32. ⟨10.1111/bjh.12090⟩. ⟨inserm-00802672⟩



Record views